Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicySelectHealth Actimmune Akeega Prior Auth Policy | …
    Ask Trek AI about this page
    CurrentSelectHealthPolicy N/A

    Actimmune and Akeega prior authorization criteria

    Customize your policy alerts

    Sign up for all SelectHealth policy alerts

    Know when SelectHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    SelectHealth prior authorization criteria for Actimmune and Akeega, including required documentation, prerequisite therapy, and PA indications for these medications under the payer's medical/drug benefit.

    Policy Summary
    PayerSelectHealth
    PolicyActimmune and Akeega prior authorization criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit required medical documentation showing diagnosis and any required prior therapy (e.g., Actimmune: diagnosis of chronic granulomatous disease or severe malignant osteopetrosis; Akeega: documented contraindication/intolerance/failure of Lynparza).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2medications covered in this extract
    All FDA-Approved IndicationsPA indication indicator for both drugs
    Plan Yearcoverage duration specified
    YESPrerequisite therapy required for Alecensa

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ~20medications referenced

    Medication Coverage Criteria

    Medication-specific coverage criteria

    Coverage is provided when the listed required information and conditions are met for each medication:

    Actimmune coverage: Provider documents diagnosis of chronic granulomatous disease OR severe malignant osteopetrosis; no hypersensitivity to Actimmune or E. coli–derived products; prior authorization requested for an FDA‑approved indication; coverage duration: Plan Year.

    Referenced chunks: 3,4,7

    Akeega coverage: Provider documents diagnosis of deleterious or suspected deleterious BRCA‑mutated metastatic castration‑resistant prostate cancer AND documents contraindication, intolerance, or failure of Lynparza; prior authorization requested for an FDA‑approved indication; coverage duration: Plan Year.

    Referenced chunks: 11,12,15,18

    Alecensa - Initial criteria

    Alecensa is covered when ALL of the following are met:

    Required diagnosis: Diagnosis of non–small cell lung cancer (NSCLC) that is ALK‑positive; tumors confirmed as anaplastic lymphoma kinase (ALK)–positive.

    Referenced chunk: 26

    Prerequisite therapy required (document prior therapy per full policy).

    Referenced chunk: 21

    Indication: Request is for an FDA‑approved indication (PA indication indicator: All FDA‑Approved Indications).

    Referenced chunk: 22

    Radicava ORS - Initial criteria

    Radicava ORS is covered when ALL of the following are met:

    Required diagnosis: Diagnosis of amyotrophic lateral sclerosis (ALS) as defined by the revised El Escorial criteria.

    Referenced chunk: 37

    Indication: Request is for an FDA‑approved indication (PA indication indicator: All FDA‑Approved Indications).

    Referenced chunk: 34

    Medication-specific authorization criteria (partial)

    Coverage decisions and authorization are guided by medication-specific required medical information and prior-therapy prerequisites as stated below.

    ALUNBRIG - FDA‑approved indications: Authorization for ALUNBRIG requires documentation of the applicable FDA‑approved indication.

    PA indication indicator: All FDA‑Approved Indications (chunk 45)

    ALUNBRIG - ALS indication: For ALS indication, required medical information: diagnosis of ALS as defined by the revised El Escorial criteria.

    Referenced chunk: 37

    ALK‑positive metastatic NSCLC indication: For metastatic NSCLC with ALK‑positive tumors, required medical information includes documentation that the patient failed, is intolerant of, or has a contraindication to Alecensa.

    Referenced chunk: 48; prerequisite therapy required (chunk 54)

    Select psychotropic agents:

    Antipsychotic agents (listed medications)

    Covered when ALL of the following are met

    Prerequisite therapy: Previous trial on at least ONE of: aripiprazole, clozapine, fluoxetine‑olanzapine, haloperidol, olanzapine, quetiapine, risperidone, or ziprasidone.

    For MDD or schizophrenia: previous trial on Rexulti required (chunk 59)

    PA requirement: Prior authorization is required (prerequisite therapy required).

    Coverage duration: Plan Year (chunk 62)

    JUXTAPID

    Covered when ALL of the following are met

    Prerequisite therapy: Previous trial of a PCSK9 inhibitor: Repatha OR Praluent, and trial of at least one statin (atorvastatin, rosuvastatin, or simvastatin) OR documented statin intolerance.

    Referenced chunk: 70 (steps include Repatha/Praluent and statin trial)

    Laboratory and genetic/clinical criteria: Untreated fasting LDL cholesterol > 500 mg/dL AND triglycerides < 300 mg/dL; AND meets one of: documented biallelic LDL receptor mutation OR both parents with untreated total cholesterol >250 mg/dL OR xanthomas before age 10.LDL >500 mg/dL; TG <300 mg/dL

    Referenced chunk: 70; exclusion: history of significant hepatic disease or alcohol abuse (chunk 69)

    PA requirement and duration: Prior authorization required; initial coverage 6 months, reauthorization coverage: Plan Year.

    Referenced chunk: 73

    Initial therapy — AQNEURSA

    Covered when ALL of the following are met for AQNEURSA:

    AQNEURSA initial criteria: 1) Patient has tried and failed ≥3 months of miglustat therapy as evidenced by lack of improvement in disease progression; 2) Patient weight ≥15 kg; 3) Genetically confirmed diagnosis (mutations in both alleles of NPC1 or NPC2 OR one‑allele mutation plus positive filipin staining or cholestane triol/oxysterols >2x ULN); 4) Patient has ≥1 neurological symptom; 5) Patient ambulatory (independently or with assistance); 6) SARA score between ≥7 and ≤34 AND either gait subtest within 2–7 OR 9‑Hole Peg Test Dominant Hand between ≥20 and ≤150 seconds; reauthorization requires fSARA score stable or improved.SARA >=7 and <=34; HPT-D >=20 and <=150s; weight >=15 kg; cholestane triol/oxysterols >2x ULN

    Referenced chunk: 80

    Initial therapy — ARCALYST

    Covered when ALL of the following are met for ARCALYST:

    ARCALYST indications: Diagnosis of cryopyrin‑associated periodic syndrome OR recurrent pericarditis OR deficiency of Interleukin‑1 Receptor Antagonist (DIRA).

    Prerequisite therapy required (chunk 117); combination with TNF‑inhibitors excluded (chunk 88)

    Adbry (initial approval) — Atopic Dermatitis

    Covered when ALL of the following are met

    Diagnosis

    • Body surface area: Greater than or equal to 10 percent body surface area involvement.>= 10%

      Referenced chunk: 100

    • Prior therapy failures: Failure of two of: topical corticosteroid; topical calcineurin inhibitor; phototherapy; oral immunomodulator (azathioprine, cyclosporine, or mycophenolate); topical PDE‑4 (Eucrisa).2 failed therapies

      Referenced chunk: 100

    PA requirement: Prior authorization required for Adbry; for reauthorization, documented every‑4‑week dosing trial for patients <100 kg who achieved clear or almost clear skin.

    Adbry (reauthorization)

    Covered for reauthorization when the specific dosing trial has been documented

    Dosing trial for responders <100 kg: For patients less than 100 kg who achieved clear or almost clear skin, a documented trial of every‑4‑week dosing has been tried prior to reauthorization.documented trial of every‑4‑week dosing

    Referenced chunk: 100

    Augtyro

    Coverage contingent on prerequisite therapy

    Prerequisite therapy required (details not included in this excerpt); document prior therapy per full policy guidance.

    Referenced chunks: 106,107

    Rozlytrek (entrectinib) Initial Authorization

    Covered when ALL of the following are met

    Indication: Diagnosis of locally advanced or metastatic ROS1‑positive NSCLC OR diagnosis of NTRK gene fusion–positive solid tumor.

    Referenced chunk: 111

    Prior therapy: Documentation of contraindication, intolerance, or failure of Rozlytrek when applicable.

    Referenced chunk: 111

    Coverage duration: Plan Year.

    Referenced chunk: 114

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications.

    Referenced chunk: 108

    AUSTEDO (deutetrabenazine) Initial Authorization

    Covered when ALL of the following are met

    Indication: Diagnosis of chorea associated with Huntington's disease OR diagnosis of tardive dyskinesia.

    Referenced chunk: 122

    Medication formulation: Medication requested must be one of: AUSTEDO, AUSTEDO XR, or AUSTEDO XR patient titration.

    Referenced chunk: 118

    Prerequisite therapy required (specifics not provided in this excerpt); document prior therapy per full policy.

    Referenced chunk: 117

    Coverage duration: Plan Year.

    Referenced chunk: 125

    PA indicator:

    Initial and reauthorization criteria for AVMAPKI FAKZYNJA

    Covered when ALL of the following are met for AVMAPKI FAKZYNJA co-pack:

    Avapritinib initial authorization criteria: 1) Diagnosis of recurrent KRAS‑mutated, recurrent low‑grade serous ovarian cancer; 2) Prior therapy including platinum‑based therapy; 3) ECOG performance status 0 or 1; 4) Patient has been treated with Mekinist OR documented medical rationale why Mekinist is inappropriate; 5) For reauthorization, documentation that there is no disease progression (progression defined as >=20% increase in sum of diameters per RECIST v1.1).

    Coverage duration: 6 months (chunk 136)

    Covered indications for AYVAKIT

    Covered when ONE of the following diagnoses is documented for AYVAKIT:

    Ayvakit indication criteria: Diagnosis of: (a) unresectable or metastatic GIST with PDGFRA exon 18 mutation including D842V; OR (b) advanced systemic mastocytosis (ASM, SM‑AHN, or MCL); OR (c) indolent systemic mastocytosis.

    PA indication indicator: All FDA‑Approved Indications (chunk 140)

    Balversa (erdafitinib) Initial Coverage Criteria

    Balversa is covered when ALL of the following are met:

    Diagnosis of locally advanced or metastatic urothelial carcinoma.

    Referenced chunk: 154

    Genetic confirmation: Confirmed FGFR3 genetic alteration.

    Referenced chunk: 154

    Prior therapy: Progression on or after at least one line of prior systemic therapy.

    Referenced chunk: 154

    PA indication: Prior authorization indicator: All FDA‑Approved Indications.

    Referenced chunk: 151

    Rufinamide Initial Coverage Criteria

    Rufinamide coverage requires documented prerequisite therapy and PA:

    Prerequisite therapy required: YES (document prior therapy per policy).

    Referenced chunk: 160

    PA indication: Prior authorization indicator: All FDA‑Approved Indications.

    Referenced chunk: 162

    Coverage duration: Plan Year.

    Referenced chunk: 157

    Indication: FDA-approved indications / seizure-related requirement

    Covered when ALL of the following are met for the seizure-related indication:

    Seizure indication requirements: Patient has inadequate seizure control despite treatment with at least ONE anti‑epileptic drug.

    Referenced chunk: 165

    Indication: Systemic lupus erythematosus or lupus nephritis

    Covered when ALL of the following are met:

    Diagnosis and activity: Diagnosis of systemic lupus erythematosus or lupus nephritis AND current active disease status documented.

    Referenced chunk: 176

    Prior therapy: Previous treatment with at least TWO of: corticosteroids, antimalarials, or immunosuppressives.

    Referenced chunk: 176

    Concomitant therapy: Plan to continue at least ONE concomitant standard treatment (corticosteroid, antimalarial, or immunosuppressive).

    Referenced chunk: 176

    Initial Therapy — Besremi (for Polycythemia Vera)

    Besremi (for Polycythemia Vera) — Covered when ALL of the following are met

    Diagnosis of Polycythemia Vera.

    Referenced chunk: 187

    Prior therapy: Inadequate response or intolerance to hydroxyurea.

    Referenced chunk: 187

    Coverage duration: Initial approval: 6 months; reauthorization: Plan Year.

    Referenced chunk: 190

    Initial Therapy — Bosulif (for Ph+ CML)

    Bosulif (for Ph+ CML) — Covered when ALL of the following are met

    Diagnosis of Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (specify phase: newly diagnosed chronic phase or chronic, accelerated, or blast phase).

    Referenced chunk: 198

    Prior therapy: For CML in chronic, accelerated, or blast phase: previous failure or intolerance to imatinib.

    Referenced chunk: 198

    Coverage duration: (No coverage duration specified in this segment).

    Referenced chunk: 194

    CML-related coverage

    Covered when ALL of the following are met

    CML indication: Patient is diagnosed with Philadelphia chromosome–positive (Ph+) CML AND is either newly diagnosed in chronic phase OR in chronic, accelerated, or blast phase.

    Referenced chunk: 198

    Prior therapy for CML: For CML in chronic, accelerated, or blast phase: patient has previous failure or intolerance to imatinib.

    Referenced chunks: 198,204

    BRAF-directed therapy coverage

    Covered when ALL of the following are met

    Melanoma BRAF: Diagnosis of BRAF V600E or V600K mutation–positive unresectable or metastatic melanoma AND intended use as combination therapy with encorafenib (Braftovi) and binimetinib (Mektovi).

    Referenced chunk: 209

    CRC BRAF: For encorafenib (Braftovi): diagnosis of BRAF V600E mutation–positive metastatic colorectal cancer AND intended use as combination therapy with cetuximab (Erbitux).

    Referenced chunk: 209

    NSCLC BRAF: Diagnosis of BRAF V600E mutation–positive metastatic non–small cell lung cancer AND intended use as combination therapy with encorafenib (Braftovi) and binimetinib (Mektovi).

    Referenced chunk: 209

    Initial therapy / Coverage conditions for Cablivi

    Covered when ALL of the following are met:

    Cablivi coverage for aTTP: 1) Diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP); 2) Therapy was started inpatient in combination with plasma exchange; 3) Coverage duration limit: 3 months; 4) Maximum therapy duration 58 days following the last day of plasma exchange.

    Calquence (acalabrutinib) Initial Coverage Criteria

    Calquence (acalabrutinib) covered when ALL of the following are met:

    Diagnosis

    • MCL specifics: If mantle cell lymphoma: (a) previously treated with at least one prior therapy OR (b) not previously treated AND ineligible for autologous HSCT with planned combination therapy.

      Preserves AND/OR logic from source

    Product: Prescribed medication is Calquence 100 mg tablet.

    Referenced chunk: 238

    Caprelsa (vandetanib) Initial Coverage Criteria

    Caprelsa (vandetanib) covered when ALL of the following are met:

    Diagnosis of symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease.

    Referenced chunk: 252

    Product: Prescribed medication is Caprelsa.

    Referenced chunk: 248

    Initial Coverage Criteria

    Covered when ALL of the following are met for the listed medication:

    Medullary thyroid cancer indication: Diagnosis of symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease (applies where relevant).

    Referenced chunk: 252

    Carglumic acid indication: Hyperammonemia due to N‑acetylglutamate synthase deficiency.

    Referenced chunk: 263

    Sapropterin indication: Hyperphenylalaninemia due to BH4‑responsive phenylketonuria.

    Referenced chunk: 263

    Exclude members with known hypersensitivity to Actimmune or to products derived from E. coli. Documentation of hypersensitivity to Actimmune or E. coli–derived products should be reviewed prior to authorization and may preclude coverage.

    No specific exclusion criteria are listed for the medications in this segment; the policy indicates N/A under exclusion criteria for these entries.

    This section explicitly states N/A for exclusion criteria, indicating no exclusions are specified in the excerpt.

    For JUXTAPID, the patient must not have certain health conditions: specifically, no history of significant hepatic disease and no alcohol abuse. Presence of these conditions is an exclusion to coverage for JUXTAPID in this policy segment.

    Use of AQNEURSA in combination with Miplyffa is expressly excluded and will not be authorized.

    Combination use of ARCALYST with a tumor necrosis factor (TNF) inhibitor is an exclusion and is not permitted under this policy section.

    The policy excludes use of the listed agent in combination with another biologic (for example: Dupixent, Xolair, Humira, Entyvio, Otezla, etc.). Concomitant biologic therapy is not allowed.

    No off-label uses, additional exclusions, or other special criteria are identified in this excerpt; the document lists these fields as N/A for the applicable entries.

    For the medications in this portion of the policy, there are no off-label uses, Part B prerequisites, age restrictions, or prescriber restrictions specified; the document indicates these items are N/A.

    No off-label uses are listed for these agents and no exclusion criteria or other special criteria are documented in this segment.

    This section contains no off‑label uses, exclusion criteria, or additional criteria; the entries are documented as N/A where applicable.

    No off‑label uses or exclusion criteria are listed in this segment of the policy.

    No explicit exclusion criteria are provided for the medication(s) referenced in this excerpt.

    This section does not list any exclusion criteria for the referenced agent(s).

    The document states N/A for exclusion criteria and off‑label uses for these agents; no explicit exclusions or not‑medically‑necessary conditions are identified here.

    No off‑label uses or exclusion criteria are listed in this section; the policy entries are marked as N/A for these fields.

    This segment explicitly states that there are no off‑label uses listed for the included medications.

    There are no explicit 'not medically necessary' conditions listed in this section of the document; the fields are recorded as N/A.

    No conditions are identified as 'not medically necessary' in this portion of the policy; the document lists the relevant fields as N/A.

    Prior Authorization, Documentation & Denial Risks

    Prior Authorization

    PA required for All FDA‑Approved Indications

    Prior authorization is required for medications when the PA Indication Indicator is set to "1 - All FDA-Approved Indications." Submit a prior authorization request for any product flagged with this indicator.

    Prior Authorization

    Alecensa: Prior authorization required

    Alecensa requires prior authorization for all FDA‑approved indications. Include documentation that the request is for an FDA‑approved use.

    Prior Authorization

    Radicava ORS: Prior authorization required

    Radicava ORS (and the Radicava ORS Starter Kit) require prior authorization for all FDA‑approved indications; submit PA prior to dispensing.

    Medication Codes & Clinical Thresholds

    Medications listedNDC|HCPCS|proprietary_names
    ADBRYAdbry (medication listed)
    CIBINQOCibinqo (medication listed)
    AUGTYROAugtyro (medication listed)
    Medications listedmixed
    BALVERSAMedication name listed
    Medications listedmixed
    RUFINAMIDEMedication name listed
    Medication identifiersNDC
    BENLYSTA 200 MG/ML SOLN A-INJBenlysta 200 mg/mL solution autoinjector (listed medication identifier)
    BENLYSTA 200 MG/ML SOLN PRSYRBenlysta 200 mg/mL solution prefilled syringe (listed medication identifier)
    inv-51: Fasting LDL — JUXTAPID threshold
    Fasting LDL (untreated)> 500 mg/dL
    ContextRequired laboratory criterion for JUXTAPID initiation (must be untreated, fasting).
    Associated requirementsAlso requires triglycerides < 300 mg/dL and documentation of genetic/family/xanthoma criteria and prior lipid-lowering therapy trials.
    inv-52: Triglycerides — JUXTAPID threshold
    Triglycerides< 300 mg/dL
    ContextMeasured with fasting LDL for JUXTAPID requests.

    Document Background & Scope

    Background information beyond the required diagnoses for each listed drug is not provided in this document segment. Relevant required diagnoses referenced include conditions such as chronic granulomatous disease or severe malignant osteopetrosis for Actimmune and deleterious or suspected BRCA‑mutated metastatic castration‑resistant prostate cancer for Akeega; providers should refer to the required medical information sections when preparing prior authorization submissions.

    Key Terms & Diagnostic Criteria

    inv-140: Actimmune indications (required documentation)
    Actimmune indicationsChronic granulomatous disease OR severe malignant osteopetrosis
    Documentation requirementProvide diagnosis documentation as required medical information for Actimmune requests.
    Exclusion noteHypersensitivity to Actimmune or E. coli derived products is listed as an exclusion that may trigger denial.
    inv-141: Akeega required diagnosis
    Akeega required diagnosisDeleterious or suspected deleterious BRCA‑mutated metastatic castration‑resistant prostate cancer (mCRPC)
    Prerequisite therapyDocumentation of contraindication, intolerance, or failure of Lynparza is required.
    Policy Summary
    PayerSelectHealth
    PolicyActimmune and Akeega prior authorization criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit required medical documentation showing diagnosis and any required prior therapy (e.g., Actimmune: diagnosis of chronic granulomatous disease or severe malignant osteopetrosis; Akeega: documented contraindication/intolerance/failure of Lynparza).
    SourceLink
    On This Page
    Medication Coverage CriteriaPrior Authorization, Documentation & Denial RisksMedication Codes & Clinical ThresholdsDocument Background & ScopeKey Terms & Diagnostic Criteria
    For listed psychotropic medications, prior authorization notes indicate prerequisite therapy is required for at least some entries.

    See 'PREREQUISITE THERAPY REQUIRED: YES' (chunk 54) and required medical information (chunk 59)

    documented trial of every‑4‑week dosing for reauth

    Referenced chunk: 100

    Prior authorization indicator: All FDA‑Approved Indications.

    Referenced chunk: 119

    Coverage duration: Plan Year.

    Referenced chunk: 157

    Prior Authorization

    ALUNBRIG: Prior authorization required

    ALUNBRIG (brigatinib) requires prior authorization for all FDA‑approved indications; include indication-specific documentation with the request.

    Step Therapy

    Psychotropic agents: Prerequisite therapy required

    Prior authorization for the listed psychotropic agents requires documentation of prerequisite therapy trials before approval.

    • Document prior trial(s) as indicated under each medication entry.
    Prior Authorization

    Prior authorization (prerequisite therapy required)

    Prior authorization is required for the listed medications; many entries indicate prerequisite therapy is required — provide required prior‑therapy documentation when requested.

    Prior Authorization

    AQNEURSA and ARCALYST: PA required

    AQNEURSA and ARCALYST require prior authorization for all FDA‑approved indications; submit the PA with the required clinical documentation.

    Prior Authorization

    PA requirements and AD-specific documentation

    Prior authorization is required for the listed medications; for some (Adbry, Cibinqo) include the AD‑specific required medical information with the PA request.

    • Include AD-specific documentation (e.g., BSA and prior therapy failures) for Adbry/Cibinqo.
    Prior Authorization

    PA applies to All FDA‑Approved Indications

    Prior authorization applies to all FDA‑approved indications for the medications flagged with PA Indication Indicator 1; ensure the PA request references the FDA‑approved indication.

    Step Therapy

    Prerequisite therapy: submit prior‑therapy documentation

    Prerequisite therapy is required where indicated (PREREQUISITE THERAPY REQUIRED = YES). For AUSTEDO and other entries marked YES, include documentation of the required prior therapy or rationale.

    Prior Authorization

    AVMAPKI FAKZYNJA & AYVAKIT: PA required

    Prior authorization is required for AVMAPKI FAKZYNJA co-pack and AYVAKIT for their FDA‑approved indications; include indication-specific documentation.

    Prior Authorization

    Listed drugs: PA required for FDA‑approved indications

    Prior authorization is required for the listed drugs and applies to all FDA‑approved indications; attach the required documentation per the medication section.

    Prior Authorization

    Benlysta: PA required

    Benlysta requires prior authorization for all FDA‑approved indications; include the PA and supporting clinical documentation.

    Documentation Required

    Medication identifiers: include product identifier

    The policy identifies specific medication identifiers (e.g., BENLYSTA 200 MG/ML SOLN A‑INJ, BENLYSTA 200 MG/ML SOLN PRSYR); use these identifiers on PA requests when applicable.

    Prior Authorization

    Besremi & Bosulif: PA and prerequisite therapy

    Prior authorization is required and prerequisite therapy is required for Besremi and Bosulif; include documentation of prior therapy trials (e.g., hydroxyurea failure for Besremi, imatinib failure for Bosulif).

    • Besremi: document inadequate response or intolerance to hydroxyurea.
    • Bosulif: document Ph+ CML diagnosis and prior failure/intolerance to imatinib when applicable.
    Prior Authorization

    PA required; coverage duration: Plan Year (unless noted)

    Prior authorization is required for the listed medications; coverage duration is generally Plan Year unless otherwise specified in the medication section.

    Prior Authorization

    PA indication scope: All FDA‑Approved Indications

    PA applies to all FDA‑approved indications for products flagged as such; ensure the PA request reflects an FDA‑approved use.

    Prior Authorization

    Cablivi: PA requires aTTP diagnosis and inpatient initiation with plasma exchange

    Cablivi prior authorization requires documentation of a diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) and documentation that therapy was initiated inpatient in combination with plasma exchange; note coverage duration limits.

    • Document inpatient initiation with plasma exchange.
    • Coverage duration: 3 months; maximum 58 days following last day of plasma exchange.
    Prior Authorization

    Calquence & Caprelsa: PA required (oncology)

    Prior authorization is required for listed oral oncology medications (e.g., Calquence 100 mg tablet and Caprelsa) for all FDA‑approved indications; include required oncology documentation.

    Prior Authorization

    PA requirement: All FDA‑Approved Indications

    Prior authorization applies to products where the PA Indication Indicator is set to cover All FDA‑Approved Indications; include required documentation per medication.

    Step Therapy

    Akeega: Step therapy (Lynparza required)

    Akeega requires step therapy: document intolerance, contraindication, or failure of Lynparza (olaparib) before Akeega will be authorized.

    • Provide records showing trial of Lynparza and reason for discontinuation (failure, intolerance, or contraindication).
    Step Therapy

    Alecensa: Prerequisite therapy documentation required

    Alecensa has a prerequisite therapy requirement; include documentation of the required prior therapy as specified in the full medication section.

    • Provide prior‑therapy details per the Alecensa section when requested.
    Step Therapy

    Step therapy requirement: document prior trials

    Entries marked "PREREQUISITE THERAPY REQUIRED" require documentation of trials of specified alternative agents before authorization will be granted.

    • Attach prior‑therapy notes, dates, durations, and outcomes.
    Step Therapy

    Step therapy / prerequisite trials: document required trials

    Step therapy requires documentation of trials of specified alternative agents (for example, antipsychotic alternatives for the antipsychotic group, and statin and PCSK9 inhibitor trials for JUXTAPID).

    • Antipsychotic group: document trial of at least one listed antipsychotic (or Rexulti for MDD/schizophrenia where indicated).
    • JUXTAPID: document statin therapy trial/intolerance and prior Repatha or Praluent trial.
    Step Therapy

    AQNEURSA & ARCALYST: Prerequisite therapy documentation required

    For AQNEURSA, the patient must have tried and failed at least 3 months of miglustat therapy; for ARCALYST, prerequisite therapy is indicated — include documentation of these prior therapies.

    • AQNEURSA: provide evidence of ≥3 months miglustat trial and lack of improvement.
    • ARCALYST: include prior‑therapy documentation per the ARCALYST entry.
    Step Therapy

    Adbry: Prerequisite/step therapy and reauthorization documentation

    Atopic dermatitis agents (Adbry) require failure of two specified prior therapies before approval; include documented prior treatments and, for reauthorization, dosing‑trial history when applicable.

    • Document failure of two listed therapies (topical corticosteroid, topical calcineurin inhibitor, phototherapy, oral immunomodulator, topical PDE‑4).
    • Reauthorization: document every‑4‑week dosing trial for responders <100 kg when applicable.
    Step Therapy

    Step therapy noted: include prior therapy details

    Where step therapy is noted (PREREQUISITE THERAPY REQUIRED = YES), provide documentation of the required prior therapies; the specific prior agents are listed in each medication's required medical information.

    Step Therapy

    Avapritinib: Mekinist step therapy requirement

    Avapritinib requires prior treatment with Mekinist or a documented medical rationale explaining why Mekinist is inappropriate; include that documentation with the PA.

    • Provide Mekinist treatment history or clinician rationale for avoiding Mekinist.
    Step Therapy

    Rufinamide: Prerequisite therapy documentation required

    Rufinamide requires documentation that prerequisite therapy was received; include prior treatment records showing the required trial(s).

    Step Therapy

    Prerequisite therapy: provide required medical information

    Prerequisite therapy requirements are documented under each medication's "Required medical information"; include the specified prior therapies when submitting a PA.

    Step Therapy

    Besremi & Bosulif: Step therapy requirements

    Besremi requires documented inadequate response or intolerance to hydroxyurea prior to authorization; Bosulif requires prior failure/intolerance to imatinib where applicable — include those records.

    • Besremi: document hydroxyurea trial and outcome.
    • Bosulif: document imatinib failure/intolerance for indicated CML phases.
    Step Therapy

    CML: Imatinib prerequisite required

    For CML in chronic, accelerated, or blast phase, document prior failure or intolerance to imatinib before seeking authorization for alternative agents.

    Note

    No prerequisite therapy required (where indicated)

    Some medication sections do not require prerequisite therapy; confirm the specific medication entry — if no prerequisite is listed, a prior‑therapy trial is not required.

    Step Therapy

    Prerequisite therapy: follow medication‑specific instructions

    When prerequisite therapy is indicated as YES, the required prior therapies and acceptable documentation are described under the medication's required medical information — provide those records with the PA.

    Documentation Required

    Actimmune: Required diagnosis documentation

    For Actimmune, provide documentation of a diagnosis of chronic granulomatous disease OR severe malignant osteopetrosis as part of the PA request.

    Documentation Required

    Akeega: Required diagnosis and prior‑therapy documentation

    For Akeega, include documentation of deleterious or suspected deleterious BRCA‑mutated metastatic castration‑resistant prostate cancer and evidence of intolerance, contraindication, or failure of Lynparza.

    • Provide pathologic/genetic confirmation of BRCAm mCRPC and Lynparza treatment history with reasons for discontinuation if applicable.
    Documentation Required

    Alecensa: Document ALK‑positive NSCLC

    Alecensa requests must include documentation of NSCLC that is ALK‑positive; indicate tumor ALK‑positive status in the medical record.

    • Provide pathology/genetic test results confirming ALK‑positive tumor status.
    Documentation Required

    Radicava ORS: ALS diagnosis documentation required

    For Radicava ORS, include documentation that the patient meets diagnostic criteria for ALS as defined by the revised El Escorial criteria.

    • Attach clinical documentation confirming ALS per the revised El Escorial criteria.
    Documentation Required

    ALUNBRIG/Alecensa: Document diagnosis and prior therapy

    For ALUNBRIG and Alecensa indications, include the documented diagnosis matching the required medical information (ALS per El Escorial for ALS indications; ALK‑positive metastatic NSCLC with prior Alecensa failure where required).

    • Provide diagnostic confirmation and prior‑therapy history as specified.
    Documentation Required

    Antipsychotic group: Prior‑trial documentation required

    For antipsychotic group requests, document prior trial(s) on at least one listed antipsychotic. If treating MDD or schizophrenia, document a prior trial of Rexulti when required.

    • List medication name(s), dates, doses, duration, and reason for discontinuation for prior trials.
    Documentation Required

    JUXTAPID: Required laboratory and prior‑therapy documentation

    JUXTAPID requests must include fasting LDL (>500 mg/dL) and triglyceride (<300 mg/dL) values, documentation supporting genetic/family/xanthoma criteria, evidence of prior statin trial or intolerance, and prior trial of Repatha or Praluent.

    • Include fasting lipid panel values and documentation of genetic/family history or xanthoma evidence.
    • Document statin trial(s) and Repatha/Praluent trial history.
    Documentation Required

    AQNEURSA: Complete required medical information

    AQNEURSA authorizations must include documentation the patient tried and failed ≥3 months of miglustat, weight ≥15 kg, genetically confirmed NPC diagnosis (per DNA analysis or filipin/elevated oxysterols), presence of ≥1 neurological symptom, ambulatory status, and SARA/HPT‑D performance measures.

    • Provide miglustat treatment records, genetic testing results, neurologic exam findings, weight, SARA score and HPT‑D or gait subtest data.
    Documentation Required

    ARCALYST: Required diagnosis documentation

    For ARCALYST, include documentation of the covered indication (CAPS, recurrent pericarditis, or DIRA) and any required prior‑therapy information.

    • Attach diagnostic evidence supporting the ARCALYST indication requested.
    Documentation Required

    Adbry: Required clinical documentation (BSA and prior failures)

    Provide clinical documentation for atopic dermatitis requests showing moderate to severe AD (≥10% BSA) and failure of two specified prior therapies; for Adbry reauthorization include dosing‑trial history when applicable.

    • Document BSA involvement, prior therapy details, and reauthorization dosing trials if applicable.
    Documentation Required

    Rozlytrek: Diagnosis and prior‑therapy documentation required

    Rozlytrek authorization requires documentation of ROS1‑positive metastatic or locally advanced NSCLC OR NTRK fusion‑positive solid tumor diagnosis and evidence of contraindication, intolerance, or failure of Rozlytrek where applicable.

    • Provide molecular testing reports confirming ROS1 or NTRK fusion and prior‑therapy history.
    Documentation Required

    AUSTEDO: Diagnosis and product documentation required

    AUSTEDO requests must include documentation of a diagnosis of chorea associated with Huntington's disease or of tardive dyskinesia and the formulation requested.

    • Specify diagnosis and product formulation (AUSTEDO, AUSTEDO XR, or titration pack).
    Documentation Required

    Avapritinib: Required clinical documentation

    Avapritinib requests must include diagnosis of recurrent KRAS‑mutated low‑grade serous ovarian cancer, prior platinum‑based therapy, ECOG 0–1, prior Mekinist treatment or documented rationale, and for reauthorization evidence of no progression per RECIST v1.1.

    • Include genetic testing, prior chemotherapy history, ECOG status, Mekinist treatment history or rationale, and imaging/RECIST data for reauthorization.
    Documentation Required

    Ayvakit: Required diagnostic documentation

    Ayvakit requests must document one of the listed indications (e.g., unresectable/metastatic GIST with PDGFRA exon 18 mutation, advanced systemic mastocytosis, or indolent systemic mastocytosis) and supporting mutation/diagnostic evidence.

    • Attach mutation testing or pathology reports supporting the selected indication.
    Documentation Required

    Balversa: FGFR3 and prior‑therapy documentation required

    Balversa authorizations must include diagnosis of locally advanced or metastatic urothelial carcinoma, confirmation of FGFR3 genetic alteration, and documentation of progression on or after at least one prior systemic therapy.

    • Provide FGFR3 testing results, prior systemic therapy history, and evidence of disease progression.
    Documentation Required

    Rufinamide: Prerequisite therapy must be documented

    Rufinamide requests must include documentation that the prerequisite therapy was received; attach prior‑therapy records showing the required trial(s).

    Documentation Required

    Seizure indications: Document inadequate control and prior AEDs

    For seizure‑related indications, document inadequate seizure control despite treatment with at least one anti‑epileptic drug when submitting a PA.

    • Provide seizure history, medications tried, durations, and documented lack of control.
    Documentation Required

    Lupus indications: Document active disease and prior treatments

    For lupus/SLE/lupus nephritis indications, document diagnosis, current active disease, prior treatment with at least two therapy classes (corticosteroids, antimalarials, immunosuppressives), and plan for continued concomitant therapy.

    • Include treatment history showing ≥2 prior therapy classes and plan for ongoing concomitant treatment.
    Denial Risk

    Missing required medical information may trigger denial

    If required medical information is missing (e.g., diagnosis, prior therapy trials, lab values, mutation testing), the request may be denied — ensure all listed required items for the medication are included.

    Denial Risk

    Actimmune: Hypersensitivity exclusion

    Actimmune exclusion: document absence of hypersensitivity to Actimmune or E. coli‑derived products. Presence of hypersensitivity is an exclusion and may lead to denial.

    Denial Risk

    Akeega: Missing diagnosis or Lynparza trial may trigger denial

    For Akeega, failure to document the required BRCA‑mutated mCRPC diagnosis or lack of a documented Lynparza intolerance/contraindication/failure may result in denial.

    Denial Risk

    Alecensa: Missing ALK‑positive diagnosis/prior therapy risks denial

    Alecensa: absence of documented ALK‑positive NSCLC or missing prior‑therapy documentation where required may trigger denial.

    Denial Risk

    Radicava ORS: ALS diagnostic confirmation required

    Radicava ORS: lack of documentation confirming ALS per the revised El Escorial criteria may result in denial.

    Denial Risk

    Alecensa: Prior‑therapy failure/intolerance documentation required

    Failure to document prior therapy failure, intolerance, or contraindication to Alecensa (where required for ALK‑positive metastatic NSCLC) may trigger denial.

    Denial Risk

    Antipsychotic group: Missing prior trial documentation risks denial

    Lack of documentation of prior trials on the specified antipsychotics (or Rexulti where indicated for MDD/schizophrenia) may lead to denial for the antipsychotic group.

    • Ensure records show medication name, dose, duration, and outcome for prior trials.
    Denial Risk

    JUXTAPID: Incomplete prerequisite documentation risks denial

    Incomplete JUXTAPID documentation (missing LDL >500 mg/dL with TG <300 mg/dL, genetic/family/xanthoma criteria, statin/PCSK9 trial evidence) may result in denial.

    • Provide fasting lipid results, genetic/family history or xanthoma evidence, statin trial history, and Repatha/Praluent trial documentation.
    Denial Risk

    Combination therapy exclusions: AQNEURSA & ARCALYST

    Use of AQNEURSA in combination with Miplyffa, or ARCALYST in combination with a TNF‑inhibitor, are explicit exclusions and may result in denial if combination therapy is documented.

    Denial Risk

    Combination biologic exclusion for AD agents

    Use in combination with another biologic (e.g., Dupixent, Xolair, Humira, Entyvio, Otezla) is an exclusion for certain AD agents and may trigger denial.

    Denial Risk

    Rozlytrek: Missing ROS1/NTRK documentation risks denial

    Rozlytrek: lack of documentation confirming ROS1‑positive NSCLC or NTRK fusion‑positive tumor, or missing evidence of contraindication/intolerance/failure of Rozlytrek where required, may result in denial.

    Denial Risk

    AUSTEDO: Diagnosis documentation required

    AUSTEDO: absence of documentation for chorea associated with Huntington's disease or for tardive dyskinesia may lead to denial.

    Denial Risk

    Avapritinib: Documentation‑based denial risks

    Lack of required documentation for Avapritinib (diagnosis, prior platinum therapy, ECOG 0–1, Mekinist trial/rationale, and reauthorization RECIST data) may lead to denial.

    Denial Risk

    Balversa: Missing FGFR3/diagnosis/prior‑therapy risks denial

    Balversa: missing FGFR3 genetic alteration confirmation, absence of documented locally advanced/metastatic urothelial carcinoma, or lack of prior systemic therapy/progression documentation may result in denial.

    Denial Risk

    Seizure control: Document inadequate control on prior AED(s)

    Failure to document inadequate seizure control despite treatment with ≥1 anti‑epileptic may trigger denial for seizure‑related indications.

    Denial Risk

    Lupus: Prior‑treatment documentation required

    For lupus/lupus nephritis indications, failure to document prior treatment with at least two of corticosteroids, antimalarials, or immunosuppressives may result in denial.

    Denial Risk

    Missing required medical information: risk of denial

    When required medical information is missing for products like Besremi or Bosulif (e.g., diagnosis or prior therapy evidence), the PA may be denied — provide the listed documentation.

    Denial Risk

    Imatinib prerequisite absent: denial risk

    Absence of documented prior failure or intolerance to imatinib for indicated CML phases may trigger denial when prerequisite therapy is required.

    Denial Risk

    Missing mutation testing (BRAF) risks denial

    Missing mutation testing (e.g., BRAF V600E or V600K) for indicated tumor types may lead to denial; include molecular testing reports with the PA.

    Documentation Required

    Cablivi: Inpatient initiation and plasma exchange documentation required

    For Cablivi, failure to document that therapy was started inpatient with plasma exchange may result in denial; include inpatient and plasma exchange documentation.

    • Submit records showing inpatient initiation and plasma‑exchange dates.
    Denial Risk

    Insufficient diagnosis/prior‑therapy documentation risks denial

    Insufficient diagnosis documentation (e.g., mantle cell lymphoma for Calquence or symptomatic/progressive medullary thyroid cancer for Caprelsa) may trigger denial; include the specific diagnostic and prior‑therapy details requested.

    Denial Risk

    Missing required diagnosis: denial risk

    Absence of a required diagnosis (e.g., symptomatic/progressive medullary thyroid cancer, hyperammonemia due to N‑acetylglutamate synthase deficiency, or BH4-responsive PKU) may lead to denial; include the specific diagnostic evidence requested.

    Note
    Note
    Note
    Note
    Note
    Note
    Associated requirementsAlso requires untreated fasting LDL > 500 mg/dL and prior trials of statin and PCSK9 inhibitors (Repatha or Praluent).
    inv-53: SARA score — AQNEURSA functional severity measure
    SARA score — required range>= 7 and <= 34 points (out of 40)
    ContextPart of AQNEURSA functional/severity measures required at initial request; used with gait subtest or HPT-D criteria.
    Reauthorization noteFor reauthorization, fSARA score must have remained stable or improved.
    inv-54: HPT-D — AQNEURSA functional test threshold
    HPT-D (9-Hole Peg Test Dominant Hand)>= 20 and <= 150 seconds
    ContextAcceptable performance range used as one of the functional criteria for AQNEURSA initiation (SCAFI subtest).
    Relation to SARAHPT-D requirement is combined with SARA score (>=7 and <=34) and gait subtest criteria for eligibility.
    inv-55: Patient weight — AQNEURSA initiation threshold
    Minimum patient weight>= 15 kg
    ContextRequired weight threshold for AQNEURSA initiation documented in required medical information.
    Documentation tipWeight must be recorded with other genetic and functional criteria to support authorization.
    inv-56: Cholestane triol/oxysterols — NPC diagnostic threshold
    Cholestane triol / oxysterols> 2x upper limit of normal
    ContextUsed to support genetically confirmed diagnosis of Niemann–Pick disease type C when only a single allele mutation is found.
    Testing noteElevated cholestane triol/oxysterols (>2x ULN) can substitute alongside single-allele mutation plus filipin staining for genetic confirmation.
    inv-57: Body Surface Area (BSA) — atopic dermatitis threshold
    Body Surface Area (BSA)>= 10 percent
    ContextRequired to define moderate to severe atopic dermatitis for Adbry coverage eligibility.
    Associated prior therapy requirementIn addition to BSA >=10%, failure of two specified topical, phototherapy, or systemic therapies is required.
    inv-58: Disease progression threshold (RECIST v1.1)
    Disease progression (RECIST v1.1)>= 20% increase in the sum of the diameters of target lesions
    ContextUsed to define disease progression for reauthorization determinations (Avapritinib section).
    Standard referenceProgression defined per RECIST version 1.1 criteria as stated in required medical information.
    PA scopePrior authorization applies for FDA‑approved indications as indicated in the policy segment.
    inv-142: ALK-positive — tumor definition
    ALK-positiveTumors are anaplastic lymphoma kinase (ALK)-positive
    ContextRequired diagnostic characterization for ALK-targeted therapies (e.g., Alecensa).
    Documentation tipConfirmatory testing results should be included in required medical information to avoid denial.
    inv-143: ALS (revised El Escorial criteria)
    ALS diagnostic standardDiagnosis of amyotrophic lateral sclerosis (ALS) as defined by the revised El Escorial criteria
    ContextRequired medical information for Radicava ORS and referenced for ALUNBRIG ALS indication.
    Denial riskAbsence of documentation confirming ALS per revised El Escorial criteria may trigger denial.
    inv-144: Revised El Escorial criteria — diagnostic standard for ALS
    Revised El Escorial criteriaDiagnostic standard for amyotrophic lateral sclerosis (ALS)
    UsagePolicy requires ALS diagnosis be defined according to the revised El Escorial criteria for authorization of related therapies.
    EvidenceRequired medical information sections reference the revised El Escorial criteria for ALS diagnoses.
    inv-145: ALK-positive metastatic NSCLC — definition for Alecensa coverage
    ALK-positive metastatic NSCLCMetastatic non-small cell lung cancer with tumors that are anaplastic lymphoma kinase (ALK)-positive
    Prerequisite therapy noteFor ALK-positive metastatic NSCLC, documentation that patient failed/intolerant/contraindicated to Alecensa is required where applicable.
    PA scopePrior authorization required for FDA-approved indications per policy.
    inv-146: Untreated, fasting LDL cholesterol >500 mg/dL — JUXTAPID lab threshold
    JUXTAPID lab thresholdUntreated, fasting LDL cholesterol >500 mg/dL
    Paired requirementMust be documented alongside triglycerides <300 mg/dL and other genetic/family/xanthoma criteria and prior therapy trials.
    Denial riskFailure to document LDL >500 mg/dL with required supporting data may trigger denial of JUXTAPID requests.
    inv-147: Genetically confirmed diagnosis for NPC — mutation criteria and tests
    Genetically confirmed diagnosis for NPCMutations in both alleles of NPC1 or NPC2 OR mutation in one allele plus positive filipin staining or elevated cholestane triol/oxysterols (>2x ULN)
    ContextRequired documentation to support AQNEURSA coverage when full biallelic mutation is not present.
    Associated requirementsAlso requires neurologic symptoms, functional measures (SARA, gait, HPT-D), and prior miglustat trial failure.
    inv-148: Functional and severity measures — SARA, gait, 9-Hole Peg Test ranges
    Functional and severity measuresSARA score 7–34; Gait subtest within 2–7 range (0–8); HPT-D between >=20 and <=150 seconds
    ContextThese combined measures are required to document disease severity and functional status for AQNEURSA initiation.
    Eligibility notePatient must also be ambulatory (independently or with assistance) and have >=1 neurologic symptom plus prior miglustat failure.
    inv-149: Moderate to severe atopic dermatitis (AD) — BSA >=10% and prior therapy failure
    Moderate to severe atopic dermatitis (AD)Body surface area (BSA) >= 10% AND failure of two prior therapies from listed topical/phototherapy/systemic options
    Required documentationProvide BSA measurement and documentation of the two failed prior therapies per policy requirements.
    Reauthorization considerationFor Adbry, reauthorization may require documentation of dosing trial (every-4-week) for responders <100 kg.
    inv-150: Rozlytrek indications
    Rozlytrek indicationsROS1-positive NSCLC OR NTRK gene fusion-positive solid tumors
    Documentation requirementMust include diagnosis and evidence of contraindication, intolerance, or failure of Rozlytrek where applicable.
    PA scopePrior authorization applies for FDA-approved indications per policy.
    inv-151: AUSTEDO indications
    AUSTEDO indicationsChorea associated with Huntington's disease OR tardive dyskinesia
    Formulations coveredAUSTEDO, AUSTEDO XR, AUSTEDO XR PATIENT TITRATION
    Documentation noteProvide diagnosis documentation per required medical information to support authorization.
    inv-152: Disease progression (RECIST v1.1)
    Disease progression definition (RECIST v1.1)>= 20% increase in sum of diameters of target lesions
    UsageApplied to determine lack of progression for reauthorization in Avapritinib section (documentation-based denial risk if missing).
    SourceRECIST version 1.1 criteria as cited in required medical information.
    inv-153: FGFR3 genetic alteration — Balversa definition
    FGFR3 genetic alterationConfirmed fibroblast growth factor receptor (FGFR3) genetic alteration
    ContextRequired for Balversa coverage in locally advanced or metastatic urothelial carcinoma.
    Prior therapyAlso requires progression on or after at least one line of prior systemic therapy.
    inv-154: Active disease — definition for lupus/lupus nephritis
    Active disease (lupus/lupus nephritis)Current active disease status must be documented
    ContextRequired medical information for lupus/lupus nephritis indications includes active disease and prior/concomitant treatments.
    Prior therapy requirementDocumentation of previous treatment with at least two of corticosteroids, antimalarials, or immunosuppressives is required.
    inv-155: Inadequate response or intolerance to hydroxyurea — Besremi prior therapy
    Inadequate response or intolerance to hydroxyureaDocumented inadequate response or intolerance to hydroxyurea is required
    ContextRequired prior-therapy criterion for Besremi (Polycythemia Vera).
    Authorization noteFailure to document this prior therapy may trigger denial.
    inv-156: Previous failure or intolerance to imatinib — Bosulif prior therapy
    Previous failure or intolerance to imatinibDocumented prior failure or intolerance to imatinib is required
    ContextPrerequisite therapy requirement for Bosulif when treating CML in chronic, accelerated, or blast phase.
    Denial riskLack of documentation of imatinib failure/intolerance may trigger denial.
    inv-157: BRAF V600E or V600K mutation-positive — mutation requirement
    BRAF V600E or V600K mutation-positiveTumor documented as harboring BRAF V600E or V600K mutation
    ContextRequired for indicated melanoma, colorectal cancer, and NSCLC BRAF-directed therapy coverage.
    Treatment pairingOften required in combination regimens as specified (e.g., encorafenib with cetuximab).
    inv-158: Philadelphia chromosome positive (Ph+) CML — definition
    Philadelphia chromosome positive (Ph+) CMLChronic myeloid leukemia with the Philadelphia chromosome (specify phase)
    ContextDiagnosis required for Bosulif coverage; phase must be specified (newly diagnosed chronic, chronic/accelerated/blast).
    Prior therapyFor chronic/accelerated/blast phases, prior failure/intolerance to imatinib is required.
    inv-159: aTTP — definition for Cablivi
    aTTPAcquired thrombotic thrombocytopenic purpura (aTTP)
    Documentation requirementTherapy must be documented as started inpatient in combination with plasma exchange for Cablivi authorization.
    Coverage limitsCoverage duration is 3 months with a maximum of 58 days of therapy following last day of plasma exchange.
    inv-160: Previously treated — Calquence prior therapy definition
    Previously treatedMember has been treated with at least one prior therapy
    ContextRequired for Calquence when member has mantle cell lymphoma and was previously treated.
    Alternative pathwayIf treatment-naïve and ineligible for autologous HSCT, Calquence may be used in combination with bendamustine and rituximab.
    inv-161: Ineligible for autologous HSCT — Calquence use-case
    Ineligible for autologous HSCTTreatment-naïve members who cannot undergo autologous hematopoietic stem cell transplantation
    ContextDefines the subgroup of mantle cell lymphoma patients for whom Calquence combined with bendamustine and rituximab is indicated.
    DocumentationDocumentation of HSCT ineligibility and planned combination therapy should be provided per required medical information.
    inv-162: N-acetylglutamate synthase deficiency — carglumic acid indication
    N-acetylglutamate synthase deficiencyInherited metabolic disorder causing hyperammonemia
    IndicationRequired diagnosis for carglumic acid authorization (hyperammonemia due to NAGS deficiency).
    DocumentationProvide diagnosis documentation per required medical information to support coverage.
    inv-163: BH4-responsive phenylketonuria — sapropterin indication
    BH4-responsive phenylketonuriaPhenylketonuria responsive to tetrahydrobiopterin (BH4)
    IndicationRequired diagnosis for sapropterin authorization (hyperphenylalaninemia due to BH4-responsive PKU).
    DocumentationProvide relevant metabolic testing and diagnostic documentation as required.